| 1  | A bill to be entitled                                  |
|----|--|
| 2  | An act relating to drug-free workplaces; amending s.   |
| 3  | 112.0455, F.S.; requiring licensed drug-testing        |
| 4  | facilities to perform prescreening tests on urine      |
| 5  | specimens to determine the specimens' validity;        |
| 6  | specifying requirements for such tests; authorizing    |
| 7  | such facilities to rely on such tests to determine if  |
| 8  | confirmation testing is required; providing that urine |
| 9  | specimens may not be sent to an out-of-state facility  |
| 10 | unless the facility complies with certain              |
| 11 | requirements; authorizing the Agency for Health Care   |
| 12 | Administration to adopt rules; conforming cross-       |
| 13 | references; amending s. 440.102, F.S.; revising        |
| 14 | definitions; revising information required in a        |
| 15 | written policy statement provided to employees and job |
| 16 | applicants before drug testing; revising procedures    |
| 17 | for specimen collection, testing, and preservation;    |
| 18 | revising qualifications for persons who may take or    |
| 19 | collect specimens for a drug test; revising            |
| 20 | requirements and procedures for retesting specimens;   |
| 21 | deleting and revising confidentiality requirements for |
| 22 | employers relating to certain information; revising    |
| 23 | circumstances under which an employer may take certain |
| 24 | actions as to an employee or a job applicant on the    |
| 25 | sole basis of certain positive test results; revising  |
|    |  |

Page 1 of 21

CODING: Words stricken are deletions; words underlined are additions.

26 standards for chain-of-custody procedures; revising 27 requirements and authorized actions relating to 28 confirmation testing; requiring licensed drug-testing 29 facilities to perform prescreening tests on urine 30 specimens to determine the specimens' validity; specifying requirements for such tests; authorizing 31 32 such facilities to rely on such tests to determine if 33 confirmation testing is required; providing that urine specimens may not be sent to an out-of-state facility 34 35 unless the facility complies with certain 36 requirements; authorizing the agency to adopt rules; 37 conforming provisions to changes made by the act; amending s. 443.101, F.S.; conforming a cross-38 39 reference; providing an effective date.

40

41 WHEREAS, the State of Florida has a profound interest in 42 the health and welfare of its citizens, and

WHEREAS, new and emerging drug-testing subversion technologies represent a significant threat to the ability to properly identify those suffering from addiction and drug abuse, and

WHEREAS, the Legislature, therefore, seeks to require urine sample validity testing, such that those persons being tested can be properly and promptly identified for referral to drug treatment programs and other health care services, NOW,

### Page 2 of 21

CODING: Words stricken are deletions; words underlined are additions.

| THEREFORE,   |
|--|
|  |
| Be It Enacted by the Legislature of the State of Florida:        |
|  |
| Section 1. Present subsections (13) through (17) of              |
| section 112.0455, Florida Statutes, are redesignated as          |
| subsections (14) through (18), respectively, a new subsection    |
| (13) is added to that section, and paragraph (b) of subsection   |
| (6) and paragraph (a) of present subsection (15) are amended, to |
| read:  |
| 112.0455 Drug-Free Workplace Act                                 |
| (6) NOTICE TO EMPLOYEES  |
| (b) Prior to testing, all employees and job applicants for       |
| employment shall be given a written policy statement from the    |
| employer which contains:   |
| 1. A general statement of the employer's policy on               |
| employee drug use, which shall identify:                         |
| a. The types of testing an employee or job applicant may         |
| be required to submit to, including reasonable suspicion or      |
| other basis; and   |
| b. The actions the employer may take against an employee         |
| or job applicant on the basis of a positive confirmed drug test  |
| result.  |
| 2. A statement advising the employee or job applicant of         |
| the existence of this section.                                   |
| Page 3 of 21   |
|  |

CODING: Words stricken are deletions; words underlined are additions.

3. A general statement concerning confidentiality.

77 Procedures for employees and job applicants to 4. 78 confidentially report the use of prescription or nonprescription 79 medications both before and after being tested. Additionally, 80 employees and job applicants shall receive notice of the most 81 common medications by brand name or common name, as applicable, 82 as well as by chemical name, which may alter or affect a drug 83 test. A list of such medications shall be developed by the Agency for Health Care Administration. 84

85

76

5. The consequences of refusing to submit to a drug test.

86 6. Names, addresses, and telephone numbers of employee
87 assistance programs and local alcohol and drug rehabilitation
88 programs.

89 7. A statement that an employee or job applicant who 90 receives a positive confirmed drug test result may contest or 91 explain the result to the employer within 5 working days after 92 written notification of the positive test result. If an employee 93 or job applicant's explanation or challenge is unsatisfactory to 94 the employer, the person may contest the drug test result as 95 provided by subsections (15) (14) and (16) (15).

8. A statement informing the employee or job applicant of his or her responsibility to notify the laboratory of any administrative or civil actions brought pursuant to this section.

100

9. A list of all drugs for which the employer will test,

### Page 4 of 21

CODING: Words stricken are deletions; words underlined are additions.

101 described by brand names or common names, as applicable, as well 102 as by chemical names.

103 10. A statement regarding any applicable collective
104 bargaining agreement or contract and the right to appeal to the
105 Public Employees Relations Commission.

106 11. A statement notifying employees and job applicants of 107 their right to consult the testing laboratory for technical 108 information regarding prescription and nonprescription 109 medication.

110 (13) DRUG-TESTING STANDARDS; SAMPLE VALIDITY 111 PRESCREENING.-Before a drug-testing facility licensed under part 112 II of chapter 408 may perform any drug-screening test on a urine 113 specimen collected in this state, prescreening tests must be 114 performed to determine the validity of the specimen. The 115 prescreening tests must be capable of detecting, or detecting 116 and defeating, novel or emerging urine drug-testing subversion 117 technologies as described in this subsection.

118 (a) The drug-testing facility shall use urine sample 119 validity screening tests that meet all of the following 120 criteria:

1211. A urine sample validity screening test for creatinine122must use a 20 mg/dL cutoff concentration and must have minimal123interferences from bilirubin and blood in the urine. The urine124sample validity screening test must be able to discriminate125between a creatinine level from an unadulterated urine sample

### Page 5 of 21

2020

| 126 | and a creatinine level arising from overhydration or creatine or   |
|-----|--|
| 127 | protein loading.   |
| 128 | 2. A urine sample validity screening test for oxidants   |
| 129 | must be able to detect the presence or effects of oxidant  |
| 130 | adulterants up to 6 days after sample collection, under the  |
| 131 | sample storage conditions outlined in the laboratory standards   |
| 132 | guideline adopted by rule by the Agency for Health Care  |
| 133 | Administration, and after any sample transport that is routinely   |
| 134 | involved.  |
| 135 | 3. Urine sample validity screening tests must be able to   |
| 136 | detect synthetic or freeze-dried urine substituted for the   |
| 137 | donor's urine for drug testing.  |
| 138 | 4. Urine sample validity screening tests must be validated   |
| 139 | for the detection of all of the additional adulterant classes  |
| 140 | represented by glutaraldehyde, salt, heavy metals, cationic  |
| 141 | detergents, protease, strong alkaline buffers, and strong acidic   |
| 142 | buffers. The detection limits of these classes must be at a  |
| 143 | sufficient level to detect a nonphysiologic sample or  |
| 144 | interference with enzyme immunoassay drug-screening tests.   |
| 145 | (b) The drug-testing facility may use only urine sample  |
| 146 | validity screening tests that have undergone validation studies  |
| 147 | conducted by the manufacturer to document the product's  |
| 148 | conformance to the requirements of this subsection.  |
| 149 |  |
| 149 | (c) A drug-testing facility may rely on urine sample   |
| 150 | (c) A drug-testing facility may rely on urine sample<br>validity screening tests to determine if confirmation testing is |

Page 6 of 21

2020

| 151 | required for any urine sample that has been deemed invalid for      |
|-----|---|
| 152 | drug screening.   |
| 153 | (d) Urine specimens collected in this state may not be              |
| 154 | sent for drug-screening tests to a drug-testing facility located    |
| 155 | outside of this state unless such drug-testing facility complies    |
| 156 | with all requirements of this subsection.                           |
| 157 | (e) The Agency for Health Care Administration shall adopt           |
| 158 | rules necessary for the implementation and enforcement of this      |
| 159 | subsection.   |
| 160 | (16) (15) NONDISCIPLINE REMEDIES                                    |
| 161 | (a) Any person alleging a violation of <del>the provisions of</del> |
| 162 | this section, that is not remediable by the commission or an        |
| 163 | arbitrator pursuant to subsection $(15)$ $(14)$ , must institute a  |
| 164 | civil action for injunctive relief or damages, or both, in a        |
| 165 | court of competent jurisdiction within 180 days of the alleged      |
| 166 | violation, or be barred from obtaining the following relief.        |
| 167 | Relief is limited to:   |
| 168 | 1. An order restraining the continued violation of this             |
| 169 | section.  |
| 170 | 2. An award of the costs of litigation, expert witness              |
| 171 | fees, reasonable <u>attorney</u> attorney's fees, and noneconomic   |
| 172 | damages provided that damages shall be limited to the recovery      |
| 173 | of damages directly resulting from injury or loss caused by each    |
| 174 | violation of this section.  |
| 175 | Section 2. Present subsections (9) through (15) of section          |
|     | Page 7 of 21  |

Page 7 of 21

440.102, Florida Statutes, are redesignated as subsections (10) through (16), respectively, a new subsection (9) is added to that section, and paragraphs (c), (e), and (q) of subsection (1), paragraph (a) of subsection (3), paragraphs (b) through (h), (j), (k), and (l) of subsection (5), subsection (6), paragraph (a) of subsection (7), and paragraphs (b) and (c) of present subsection (9) of that section are amended, to read:

183 440.102 Drug-free workplace program requirements.—The 184 following provisions apply to a drug-free workplace program 185 implemented pursuant to law or to rules adopted by the Agency 186 for Health Care Administration:

187 (1) DEFINITIONS.-Except where the context otherwise188 requires, as used in this act:

189 (C) "Drug" means any form of alcohol, as defined in s. 190 322.01(2), including a distilled spirit, wine, a malt beverage, 191 or an intoxicating preparation; any controlled substance 192 identified under Schedule I, Schedule II, Schedule III, Schedule IV, or Schedule V of s. 893.03; any controlled substance 193 194 identified under Schedule I, Schedule II, Schedule III, Schedule IV, or Schedule V of the Controlled Substances Act, 21 U.S.C. s. 195 196 812(c) liquor; an amphetamine; a cannabinoid; cocaine; phencyclidine (PCP); a hallucinogen; methaqualone; an opiate; a 197 barbiturate; a benzodiazepine; a synthetic narcotic; a designer 198 drug; or a metabolite of any of the substances listed in this 199 200 paragraph. An employer may test an individual for any or all of

Page 8 of 21

CODING: Words stricken are deletions; words underlined are additions.

201 such drugs.

202 (e) "Drug test" or "test" means any chemical, biological, 203 or physical instrumental analysis administered, by a laboratory 204 certified by the United States Department of Health and Human 205 Services or licensed by the Agency for Health Care 206 Administration  $\tau$  for the purpose of determining the presence or 207 absence of a drug or its metabolites. In the case of testing for 208 the presence of alcohol, the test must be conducted in 209 accordance with the United States Department of Transportation 210 alcohol testing procedures authorized under 49 C.F.R. part 40, 211 subparts J through M.

(q) "Specimen" means tissue, hair, or a product of the human body capable of revealing the presence of drugs or their metabolites, as approved by the United States Food and Drug Administration, or the Agency for Health Care Administration, the United States Department of Health and Human Services, or the United States Department of Transportation.

218

(3) NOTICE TO EMPLOYEES AND JOB APPLICANTS.-

(a) One time only, <u>before</u> prior to testing, an employer
 shall give all employees and job applicants for employment a
 written policy statement <u>that</u> which contains:

A general statement of the employer's policy on
 employee drug use, which must identify:

224 a. The types of drug testing an employee or job applicant 225 may be required to submit to, including reasonable-suspicion

### Page 9 of 21

CODING: Words stricken are deletions; words underlined are additions.

226 drug testing or drug testing conducted on any other basis.

227 b. The actions the employer may take against an employee 228 or job applicant on the basis of a positive confirmed drug test 229 result.

2. A statement advising the employee or job applicant ofthe existence of this section.

232

3. A general statement concerning confidentiality.

4. Procedures for employees and job applicants to
confidentially report to a medical review officer the use of
prescription or nonprescription medications to a medical review
officer both before and after being tested.

5. A list of the most common medications, by brand name or common name, as applicable, as well as by chemical name, which may alter or affect a drug test. A list of such medications as developed by the Agency for Health Care Administration shall be available to employers through the department.

242

6. The consequences of refusing to submit to a drug test.

7. A representative sampling of names, addresses, and
telephone numbers of employee assistance programs and local drug
rehabilitation programs.

8. A statement that an employee or job applicant who receives a positive confirmed test result may contest or explain the result to the medical review officer within 5 working days after receiving written notification of the test result; that if an employee's or job applicant's explanation or challenge is

### Page 10 of 21

unsatisfactory to the medical review officer, the medical review officer shall report a positive test result back to the employer; and that a person may contest the drug test result pursuant to law or to rules adopted by the Agency for Health Care Administration.

9. A statement informing the employee or job applicant of
his or her responsibility to notify the laboratory of any
administrative or civil action brought pursuant to this section.

259 10. A list of all drugs for which the employer will test,
260 described by brand name or common name, as applicable, as well
261 as by chemical name.

262 11. A statement regarding any applicable collective
263 bargaining agreement or contract and the right to appeal to the
264 Public Employees Relations Commission or applicable court.

265 12. A statement notifying employees and job applicants of 266 their right to consult with a medical review officer for 267 technical information regarding prescription or nonprescription 268 medication.

(5) PROCEDURES AND EMPLOYEE PROTECTION.—All specimen
 collection and testing for drugs under this section shall be
 performed in accordance with the following procedures:

(b) Specimen collection must be documented, and the
 documentation procedures shall include <u>the</u>:

274 1. labeling of specimen containers so as to reasonably
275 preclude the likelihood of erroneous identification of test

### Page 11 of 21

CODING: Words stricken are deletions; words underlined are additions.

2020

| 276 | results. For saliva or breath alcohol testing, a specimen                         |
|-----|---|
| 277 | container is not required if the specimen is not being                            |
| 278 | transported to a laboratory for analysis  |
| 279 | 2. A form for the employee or job applicant to provide any                        |
| 280 | information he or she considers relevant to the test, including                   |
| 281 | identification of currently or recently used prescription or                      |
| 282 | nonprescription medication or other relevant medical                              |
| 283 | information. The form must provide notice of the most common                      |
| 284 | medications by brand name or common name, as applicable, as well                  |
| 285 | as by chemical name, which may alter or affect a drug test. The                   |
| 286 | providing of information shall not preclude the administration                    |
| 287 | of the drug test, but shall be taken into account in                              |
| 288 | interpreting any positive confirmed test result.                                  |
| 289 | (c) Specimen collection, storage, and transportation to $\underline{a}$           |
| 290 | <u>laboratory</u> <del>the testing site</del> shall be performed in a manner that |
| 291 | reasonably precludes contamination or adulteration of specimens.                  |
| 292 | (d) Each confirmation test conducted under this section,                          |
| 293 | not including the taking or collecting of a specimen to be                        |
| 294 | tested, shall be conducted by a licensed or certified laboratory                  |
| 295 | as described in subsection $(10)$ (9).  |
| 296 | (e) A specimen for a drug test may be taken or collected                          |
| 297 | by any person who meets the qualification standards for urine or                  |
| 298 | oral fluid specimen collection as specified by the United States                  |
| 299 | Department of Health and Human Services or the United States                      |
| 300 | Department of Transportation. For alcohol testing, a person must                  |
|     | Dogo 10 of 01   |

## Page 12 of 21

301 meet the United States Department of Transportation standards 302 for a screening test technician or a breath alcohol technician. 303 A hair specimen may be collected and packaged by a person who 304 has been trained and certified by a drug-testing laboratory. A 305 person who directly supervises an employee subject to testing 306 may not serve as the specimen collector for that employee unless 307 there is no other qualified specimen collector available of the 308 following persons: 309 1. A physician, a physician assistant, a registered 310 professional nurse, a licensed practical nurse, or a 311 practitioner or a certified paramedic who is present at the 312 scene of an accident for the purpose of rendering emergency 313 medical service or treatment. 314 2. A qualified person employed by a licensed or 315 laboratory as described in subsection (9). 316 (f) A person who collects or takes a specimen for a drug 317 test shall collect an amount sufficient for two independent drug tests, one to screen the specimen and one for confirmation of 318 the screening test results, at a laboratory as determined by the 319 320 Agency for Health Care Administration. 321 Every specimen that produces a positive, confirmed (q) 322 test result shall be preserved by the licensed or certified laboratory that conducted the confirmation test for a period of 323 324 at least 1 year after the confirmation test was conducted 210 days after the result of the test was mailed or otherwise 325

### Page 13 of 21

CODING: Words stricken are deletions; words underlined are additions.

2020

delivered to the medical review officer. However, if an employee 326 327 or job applicant undertakes an administrative or legal challenge 328 to the test result, the employee or job applicant shall notify 329 the laboratory and the sample shall be retained by the 330 laboratory until the case or administrative appeal is settled. 331 During the 60-day 180-day period after written notification of a 332 positive test result, the employee or job applicant who has provided the specimen shall be permitted by the employer to have 333 334 a portion of the specimen retested, at the employee's or job 335 applicant's expense, at another laboratory, licensed and 336 approved by the Agency for Health Care Administration, chosen by 337 the employee or job applicant. The second laboratory must test the specimen at the limit of detection for the drug or analyte 338 339 confirmed by the original at equal or greater sensitivity for 340 the drug in question as the first laboratory. If the drug or 341 analyte is detected by the second laboratory, the result must be 342 reported as reconfirmed positive. The first laboratory that 343 performed the test for the employer is responsible for the 344 transfer of the portion of the specimen to be retested, and for 345 the integrity of the chain of custody during such transfer. 346 Within 5 working days after receipt of a positive (h) 347 verified confirmed test result from the medical review officer, an employer shall inform an employee or job applicant in writing 348 of such positive test result, the consequences of such result 349 350 results, and the options available to the employee or job

### Page 14 of 21

applicant. The employer shall provide to the employee or jobapplicant, upon request, a copy of the test results.

353 The employee's or job applicant's explanation or (j) 354 challenge of the positive test result is unsatisfactory to the 355 employer, a written explanation as to why the employee's or job 356 applicant's explanation is unsatisfactory, along with the report 357 of positive result, shall be provided by the employer to the 358 employee or job applicant; and All such documentation of a 359 positive test shall be kept confidential by the employer pursuant to subsection (8) and shall be retained by the employer 360 361 for at least 1 year.

362 (k) An employer may not discharge, discipline, refuse to 363 hire, discriminate against, or request or require rehabilitation 364 of an employee or job applicant on the sole basis of a positive 365 test result that has not been reviewed and verified by a 366 confirmation test and by a medical review officer, except when a 367 confirmed positive breath alcohol test was conducted in accordance with United States Department of Transportation 368 369 alcohol testing procedures.

(1) An employer that performs drug testing or specimen
collection shall use chain-of-custody procedures established by
the Agency for Health Care Administration, the United States
<u>Department of Health and Human Services</u>, or the United States
<u>Department of Transportation</u> to ensure proper recordkeeping,
handling, labeling, and identification of all specimens tested.

#### Page 15 of 21

CODING: Words stricken are deletions; words underlined are additions.

| 376 | (6) CONFIRMATION TESTING  |
|-----|---|
| 377 | (a) If an initial drug test is negative, the employer may                           |
| 378 | in its sole discretion seek a confirmation test.                                    |
| 379 | (b) Only licensed or certified laboratories as described                            |
| 380 | in subsection (9) may conduct confirmation drug tests.                              |
| 381 | <del>(c)</del> All <u>laboratory</u> positive initial tests <u>on a urine, oral</u> |
| 382 | fluid, blood, or hair specimen shall be confirmed using gas                         |
| 383 | chromatography/mass spectrometry (GC/MS) or an equivalent or                        |
| 384 | more accurate scientifically accepted method approved by the                        |
| 385 | United States Department of Health and Human Services or the                        |
| 386 | United States Department of Transportation Agency for Health                        |
| 387 | Care Administration or the United States Food and Drug                              |
| 388 | Administration as such technology becomes available in a cost-                      |
| 389 | effective form.   |
| 390 | <u>(b)</u> (d) If <u>a</u> <del>an initial</del> drug test of an employee or job    |
| 391 | applicant is confirmed by the laboratory as positive, the                           |
| 392 | employer's medical review officer shall provide technical                           |
| 393 | assistance to the employer and to the employee or job applicant                     |
| 394 | for the purpose of interpreting the test result to determine                        |
| 395 | whether the result could have been caused by prescription or                        |
| 396 | nonprescription medication taken by the employee or job                             |
| 397 | applicant.  |
| 398 | (c) For a breath alcohol test, an initial positive result                           |
| 399 | must be confirmed by a second breath specimen taken and tested                      |
| 400 | using an evidential breath testing device listed on the                             |
|     |   |

# Page 16 of 21

CODING: Words stricken are deletions; words underlined are additions.

2020

| conforming products list issued by the National Highway Traffic  |
|--|
|  |
| Safety Administration and conducted in accordance with United    |
| States Department of Transportation alcohol testing procedures   |
| authorized under 49 C.F.R. part 40, subparts J through M.        |
| (7) EMPLOYER PROTECTION  |
| (a) An employee or job applicant whose drug test result is       |
| confirmed or verified as positive in accordance with this        |
| section shall not, by virtue of the result alone, be deemed to   |
| have a "handicap" or "disability" as defined under federal,      |
| state, or local handicap and disability discrimination laws.     |
| (9) DRUG-TESTING STANDARDS; SAMPLE VALIDITY PRESCREENING         |
| Before a drug-testing facility licensed under part II of chapter |
| 408 may perform any drug-screening test on a urine specimen      |
| collected in this state, prescreening tests must be performed to |
| determine the validity of the specimen. The prescreening tests   |
| must be capable of detecting, or detecting and defeating, novel  |
| or emerging urine drug-testing subversion technologies as        |
| described in this subsection.                                    |
| (a) The drug-testing facility shall use urine sample             |
| validity screening tests that meet all of the following          |
| <u>criteria:</u>   |
| 1. A urine sample validity screening test for creatinine         |
| must use a 20 mg/dL cutoff concentration and must have minimal   |
| interferences from bilirubin and blood in the urine. The urine   |
| sample validity screening test must be able to discriminate      |
|  |
|  |

Page 17 of 21

2020

| 426                                    | between a creatinine level from an unadulterated urine sample   |
|--|---|
| 427                                    | and a creatinine level arising from overhydration or creatine or  |
| 428                                    | protein loading.  |
| 429                                    | 2. A urine sample validity screening test for oxidants  |
| 430                                    | must be able to detect the presence or effects of oxidant   |
| 431                                    | adulterants up to 6 days after sample collection, under the   |
| 432                                    | sample storage conditions outlined in the laboratory standards  |
| 433                                    | guideline adopted by rule by the Agency for Health Care   |
| 434                                    | Administration, and after any sample transport that is routinely  |
| 435                                    | involved.   |
| 436                                    | 3. Urine sample validity screening tests must be able to  |
| 437                                    | detect synthetic or freeze-dried urine substituted for the  |
| 438                                    | donor's urine for drug testing.   |
| 439                                    | 4. Urine sample validity screening tests must be validated  |
| 440                                    | for the detection of all of the additional adulterant classes   |
| 441                                    | represented by glutaraldehyde, salt, heavy metals, cationic   |
| 110                                    |   |
| 442                                    | detergents, protease, strong alkaline buffers, and strong acidic  |
| 442                                    | detergents, protease, strong alkaline buffers, and strong acidic buffers. The detection limits of these classes must be at a  |
|  |   |
| 443                                    | buffers. The detection limits of these classes must be at a   |
| 443<br>444                             | buffers. The detection limits of these classes must be at a sufficient level to detect a nonphysiologic sample or   |
| 443<br>444<br>445                      | buffers. The detection limits of these classes must be at a sufficient level to detect a nonphysiologic sample or interference with enzyme immunoassay drug-screening tests.  |
| 443<br>444<br>445<br>446               | buffers. The detection limits of these classes must be at a<br>sufficient level to detect a nonphysiologic sample or<br>interference with enzyme immunoassay drug-screening tests.<br>(b) The drug-testing facility may use only urine sample   |
| 443<br>444<br>445<br>446<br>447        | buffers. The detection limits of these classes must be at a<br>sufficient level to detect a nonphysiologic sample or<br>interference with enzyme immunoassay drug-screening tests.<br>(b) The drug-testing facility may use only urine sample<br>validity screening tests that have undergone validation studies  |
| 443<br>444<br>445<br>446<br>447<br>448 | <pre>buffers. The detection limits of these classes must be at a sufficient level to detect a nonphysiologic sample or interference with enzyme immunoassay drug-screening tests.     (b) The drug-testing facility may use only urine sample validity screening tests that have undergone validation studies conducted by the manufacturer to document the product's</pre> |

Page 18 of 21

| FL | 0 | RΙ | D | А | Н | 0 | U | S | Е | 0 | F | R | Е | Ρ | R | Е | S | Е | Ν | Т | А | Т |  | V | Е | S |
|----|---|----|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|--|---|---|---|
|----|---|----|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|--|---|---|---|

461

464

471

451 validity screening tests to determine if confirmation testing is 452 required for any urine sample that has been deemed invalid for 453 drug screening. 454 (d) Urine specimens collected in this state may not be 455 sent for drug-screening tests to a drug-testing facility located 456 outside of this state unless such drug-testing facility complies 457 with all requirements of this subsection. 458 (e) The Agency for Health Care Administration shall adopt 459 rules necessary for the implementation and enforcement of this 460 subsection. (10) (9) DRUG-TESTING STANDARDS FOR LABORATORIES.-462 (b) A laboratory may analyze initial or confirmation test 463 specimens only if: The laboratory obtains a license under part II of 1. 465 chapter 408 and s. 112.0455(18) s. 112.0455(17). Each applicant 466 for licensure and each licensee must comply with all 467 requirements of this section, part II of chapter 408, and 468 applicable rules. 469 2. The laboratory has written procedures to ensure the 470 chain of custody. 3. The laboratory follows proper quality control 472 procedures, including, but not limited to: 473 The use of internal quality controls, including the use a. 474 of samples of known concentrations which are used to check the 475 performance and calibration of testing equipment, and periodic

### Page 19 of 21

CODING: Words stricken are deletions; words underlined are additions.

476 use of blind samples for overall accuracy.

b. An internal review and certification process for drug
test results, conducted by a person qualified to perform that
function in the testing laboratory.

480 c. Security measures implemented by the testing laboratory481 to preclude adulteration of specimens and drug test results.

482 d. Other necessary and proper actions taken to ensure483 reliable and accurate drug test results.

(c) A laboratory shall disclose to the medical review officer a written positive confirmed test result report within 7 working days after receipt of the sample. All laboratory reports of a drug test result must, at a minimum, state:

488 1. The name and address of the laboratory that performed489 the test and the positive identification of the person tested.

490 2. Positive results on confirmation tests only, or491 negative results, as applicable.

492 3. A list of the drugs for which the drug analyses were493 conducted.

494 4. The type of tests conducted for both initial tests and 495 confirmation tests and the minimum cutoff levels of the tests.

496 5. Any correlation between medication reported by the 497 employee or job applicant pursuant to subparagraph (5) (b)2. and 498 a positive confirmed drug test result.

499

500 A report must not disclose the presence or absence of any drug

#### Page 20 of 21

CODING: Words stricken are deletions; words underlined are additions.

501 other than a specific drug and its metabolites listed pursuant 502 to this section.

503 Section 3. Paragraph (b) of subsection (11) of section 504 443.101, Florida Statutes, is amended to read:

505 443.101 Disqualification for benefits.—An individual shall 506 be disqualified for benefits:

507 (11) If an individual is discharged from employment for 508 drug use as evidenced by a positive, confirmed drug test as provided in paragraph (1)(d), or is rejected for offered 509 employment because of a positive, confirmed drug test as 510 511 provided in paragraph (2)(c), test results and chain of custody 512 documentation provided to the employer by a licensed and 513 approved drug-testing laboratory is self-authenticating and 514 admissible in reemployment assistance hearings, and such 515 evidence creates a rebuttable presumption that the individual 516 used, or was using, controlled substances, subject to the 517 following conditions:

(b) Only laboratories licensed and approved as provided in <u>s. 440.102(10)</u> <del>s. 440.102(9),</del> or as provided by equivalent or more stringent licensing requirements established by federal law or regulation may perform the drug tests.

522

Section 4. This act shall take effect July 1, 2020.

### Page 21 of 21

CODING: Words stricken are deletions; words underlined are additions.